Marksans Pharma Ltd Company History

Company has changed its name from Tasc Pharmaceuticals Ltd. to Marksans Pharma Ltd.

In 2005, Marksans acquired Nova Australasia Pty Ltd. (Nova), an Australian marketing company that specializes in marketing OTC and pharmaceutical products. The company has robust operating margins and a presence across top pharmacies and major chain stores for the distribution of generics and OTC products.

Marksans Pharma Ltd has informed that the Board of Directors of the Company at its meeting held on October 30, 2006 has appointed Mr V Nagaraj as Additional as well as Whole Time Director (marketing) of the Company.

Marksans Pharma Limited has appoineted Mr. V. Nagaraj as Additional as well as Whole Time Director (marketing) of the Company.

The Company has splits its face value from Rs10/- to Rs1/-.

Registered Office of the Company has been shifted From 601-622, Chintamani Plaza, Mohan Studio Compound, Andheri-Kurla Road, Andheri (E), Mumbai 400 099 To 21st Floor, Lotus Business Park, Off New Link Road, Andheri (W), Mumbai 400 0530.

In 2008, Marksans acquired UK's Hale Group along with its subsidiary company Bell, Sons & Co. (Druggists) Ltd. (Bell).

In August 2008, Marksans acquired Relonchem Ltd. The company is engaged in licensing, marketing and distribution of generic pharmaceutical products to wholesalers, retailers and hospitals in the UK.

"Marksans Pharma Limited announces USFDA approval of generic Ibuprofen Capsules (Liquid Filled), 200 mg for Advil Liqui - Gels 200 mg."

Company has entered into a Business Transfer Agreement with Kores (India) Limited

Registered Office of the Company has been shifted From 21st Floor, Lotus Business park, Off New Link Road, Andheri (W), Mumbai - 400053 To 11th Floor, Lotus Business Park, Off New Link Road, Andheri (W), Mumbai - 400053.

Dr. Balwant Shankarrao Desai has been appointed as a Whole-time Director of the Company

Mr. Ajay S. Joshi has been appointed as a Director of the Company

Marksans Pharma Ltd has appointed Mr. Naresh Balwant Wadhwa as an additional Director of the Company. Mr. Wadhwa will be an independent non-executive director.

Marksans Pharma Ltd has recommended dividend of 10% which is Rs. 0.10 per equity share of Rs. 1/- each face value.

The Registered office of the company has been shifted from old location to 11th Floor, "GRANDEUR", Opp. Gundeecha Symphony, Veera Desai Extension Road, Oshiwara, Andheri (W), Mumbai -400053, Telephone: +91 22 4001 2000,Telefax: +91 224001 2011, E-mail:

[email protected]

Marksans Pharma gains on acquiring Time-Cap Laboratories

Marksans Pharma gets USFDA nod for Paricalcitol capsules

Marksans Pharma gets USFDA nod for diabetes treatment drug

Marksans Pharma bags USFDA approval for Loratadine

Marksans Pharma Goa plant gets UK MHRA approval

Marksans Pharma said that it has received certificate of GMP Compliance of a Manufacturer from Australian government, Department of Health, Therapeutic Goods Administration.

Marksans Pharma received USFDA approval for Acetaminophen ER Tablets.

Company has completed the process of acquiring 100% share capital of Access Healthcare for Medical Products LLC based in Dubai, UAE.

Marksans Pharma received USFDA approval for Cetirizine Hydrochloride Tablets.

Marksans Pharma received UK MHRA approval for Bells Healthcare All in One Oral Solution.

"Marksans Pharma Limited''s wholly owned subsidiary Relonchem Limited, received Marketing Authorisation for the product Cyanocobalamin 50mg film coated tablets".

Marksans Pharma completed the acquisition from Tevapharm India, expanding the existing manufacturing capacity in India.

Marksans Pharma received UK MHRA approval for Fluoxetine 20mg/5ml Oral Solution.